By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Technologiepark 4

Ghent  Zwijnaarde  9052  Belgium
Phone: 32-0-9-261-06-32 Fax: 32-0-9-261-06-28


Company News
Ablynx (ABLYF), Novo Nordisk A/S (NVO) Ink Nanobody Pact Worth $399 Million+ 11/25/2015 10:07:32 AM
Ablynx (ABLYF) Provides Business Update For The First Nine Months Of 2015 11/18/2015 9:39:05 AM
Ablynx (ABLYF)’s Partner Boehringer Ingelheim Presented Positive In Vivo Proof-Of-Mechanism Data With Bi-Specific Nanobody At Euro Global Summit On Cancer Therapy 11/5/2015 10:54:42 AM
Ablynx (ABLYF) Achieves First Milestone In Immuno-Oncology Collaboration With Merck & Co. (MRK) 10/15/2015 10:56:08 AM
Ablynx (ABLYF) Initiates A Multinational Phase III Study With Caplacizumab In Patients With Acquired TTP, A Rare Blood Clotting Disorder 9/29/2015 9:01:25 AM
Ablynx (ABLYF) Announces Half-Year Results For 2015 8/27/2015 9:15:23 AM
Ablynx (ABLYF) Significantly Expands Its Immuno-Oncology Collaboration With Merck & Co. (MRK) 7/22/2015 2:17:55 PM
Ablynx (ABLYF) Announces Extension Of Ion Channel Research Collaboration With Merck & Co. (MRK) 3/26/2015 10:39:44 AM
Ablynx (ABLYF) Initiates The First Of Two Phase IIb Ra Studies With Its Anti-Il-6R Nanobody, Partnered With AbbVie (ABBV) 3/17/2015 7:19:27 AM
Ablynx (ABLYF) Announces Warrant Exercise 3/16/2015 8:02:56 AM